Lipigon Pharmaceuticals (“Lipigon”) announced today that it has entered into a Target Validation Research Agreement with Munich-based antisense therapeutics company Secarna Pharmaceuticals (“Secarna”). The goal is to co-develop a best-in-class drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases.
“We are very pleased for this exciting opportunity to work together with Secarna, bringing forward what we believe will be the most powerful plasma lipid lowering agent on the market”, stated CEO and co-founder Stefan K. Nilsson. He added, “This agreement utilizes Secarna’s state of the art next generation antisense platform technology and our lipid biology expertise. The lead time from choosing targets to actually validating the product candidate is exceptionally short, therefore the antisense approach is extremely attractive to us”.
Dyslipidemia indications span from very rare diseases like Familial Chylomicronemia Syndrome (FCS) or Homozygote Familial Hypercholesterolemia with 3-5000 patients worldwide to broad indications like cardiovascular disease, metabolic liver diseases and kidney disease. There are over 60 million patients at risk in G7 due to dyslipidemia and only 12 % of high risk patients meet their combined plasma lipid goals.
Antisense technology significantly expands the universe of potentially druggable targets and is currently experiencing strong growth. Well over 100 clinical trials are ongoing or have completed recently. With several drug approvals last year, this could be considered the definitive breakthrough of this technology.
“Targeting lipid disorders via antisense oligonucleotides is an extremely attractive proposition,” commented Secarna’s CEO Jonas Renz. “We are delighted to leverage Lipigon’s unique insights into lipid biology and apply our proprietary platform to generating highly potent and safe lead molecules”.
About Secarna Pharmaceuticals
Founded in 2015 and headquartered in Marburg and Munich, Germany, Secarna is a leading antisense drug development company. Secarna’s expertise spans the entire pre-clinical drug discovery and development process from proprietary bioinformatic analysis and molecule engineering to high throughput in vitro and in vivo screening systems. The company currently has over ten ongoing projects in various therapeutic areas, including immuno-oncology, immunology, ophthalmology, fibrosis, neurodegenerative disorders, and anti-viral therapeutics. For more information please visit: www.secarna.com
About Lipigon Pharmaceuticals
Lipigon was founded by leading scientists in the field lipid biology. Lipigon is currently focusing on the discovery and development of first-in-class treatments for lipid related diseases in the orphan space. For more information please visit: www.lipigon.se
For further information, please contact: Stefan K. Nilsson, CEO, Lipigon Pharmaceuticals e-mail: firstname.lastname@example.org Tel: +46 70 578 17 68
Downloads: Press release as PDF